(VXRT) – PRNewswire
-
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
-
New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model
-
Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
-
Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer
-
Vaxart To Present at Upcoming Vaccine Conferences
-
Vaxart Announces Creation of Manufacturing and Quality Advisory Board
-
Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30
-
Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
-
Vaxart Announces Creation of New Scientific and Clinical Advisory Board
-
Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
-
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
-
Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
-
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
-
Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
-
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
Back to VXRT Stock Lookup